1,3-Diazepine: A privileged scaffold in medicinal chemistry

Med Res Rev. 2021 Jul;41(4):2247-2315. doi: 10.1002/med.21795. Epub 2021 Mar 1.

Abstract

Privileged structures have been widely used as effective templates for drug discovery. While benzo-1,4-diazepine constitutes the first historical example of such a structure, the 1,3 analogue is just as rich in terms of applications in medicinal chemistry. The 1,3-diazepine moiety is present in numerous biological active compounds including natural products, and is used to design compounds displaying a large range of biological activities. It is present in the clinically used anticancer compound pentostatin, in several recent FDA approved β-lactamase inhibitors (e.g., avibactam) and also in coformycin, a natural product known as a ring-expanded purine analogue displaying antiviral and anticancer activities. Several other 1,3-diazepine containing compounds have entered into clinical trials. This heterocyclic structure has been and is still widely used in medicinal chemistry to design enzyme inhibitors, GPCR ligands, and so forth. This review endeavours to highlight the main use of the 1,3-diazepine scaffold and its derivatives, and their applications in medicinal chemistry, drug design, and therapy. We will focus more particularly on the development of enzyme inhibitors incorporating this scaffold, with a strong emphasis on the molecular interactions involved in the inhibition mechanism.

Keywords: GPCR ligands; biological activities; diazepine; enzyme inhibitors.

Publication types

  • Review

MeSH terms

  • Chemistry, Pharmaceutical
  • Drug Discovery
  • Humans
  • Ligands
  • Receptors, G-Protein-Coupled*
  • Signal Transduction*

Substances

  • Ligands
  • Receptors, G-Protein-Coupled